Bhopal: In a major development for pharmacy aspirants, a total of 14,128 seats in B.Pharmacy and D.Pharmacy courses have been allotted during the first round of counselling in Madhya Pradesh. Despite the large number of allotments, more than 5,200 seats still remain vacant, paving the way for the second round of admissions. As per official figures, 10,413 seats in B.Pharmacy and 3,715 seats in D.Pharmacy have been allotted across institutes in the state. The counselling process involved 179 B.Pharmacy institutes and 194 D.Pharmacy institutes. Candidates who have been allotted seats are required to report to their respective institutes and complete the document verification process by September 18. The second round of counselling will be conducted online between September 19 and October 3 to fill the remaining vacant seats. Dainik Bhaskarreports that the allotment and admission schedule has been carried out under state guidelines to ensure transparency in the process. Officials highlighted that the vacancies from the first round will be carried forward to the second round to maximise enrolments.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!